New Trends in the Treatment of Schizophrenia.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  CNS and Neurological Disorders - Drug Targets

• Publication date

  2017-09-30

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.2174/1871527316666170728165355PMID 28758583
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Effect of Cognitive Behavior Intervention on Violent Behavior in Female Patients with Schizophrenia

  2025cites this paper
• An Epileptic Girl With Erotomania Using Carbamazepine|Resistant to Treatment and Challenge of Starting Clozapine

  2025cites this paper
• Beyond vertebrates: Drosophila melanogaster as a model to study negative symptoms of schizophrenia

  2025cites this paper
• A molecular mechanism mediating clozapine-enhanced sensorimotor gating

  2025cites this paper
• Treatment of antipsychotic-induced hyperprolactinemia: an umbrella review of systematic reviews and meta-analyses

  2024cites this paper
• External Validation of the Population Pharmacokinetic Models of Amisulpride and Remedial Strategies for Delayed or Missed Doses

  2024cites this paper
• Current emerging therapeutic targets and clinical investigational agents for schizophrenia: Challenges and opportunities

  2024cites this paper
• Effect of 5-HT1A receptor partial agonists of the azapirone class as an add-on therapy on psychopathology and cognition in schizophrenia: A systematic review and meta-analysis.

  2023cites this paper
• Limited Predictive Performance of Existing Amisulpride PopPK Models: External Validation and Proposal of Model-Based Remedial Regimens for Non-Adherence

  2023cites this paper
• TLR/mTOR inflammatory signaling pathway: novel insight for the treatment of schizophrenia.

  2023cites this paper
• Augmentation therapy with serotonin1A receptor partial agonists on neurocognitive function in schizophrenia: A systematic review and meta-analysis

  2023cites this paper
• Trends in prescription of psychotropic medications to children in China from 2013 to 2016.

  2023cites this paper
• Schizophrenia: a disorder of broken brain bioenergetics

  2022cites this paper
• Environmentally-relevant concentrations of the antipsychotic drugs sulpiride and clozapine induce abnormal dopamine and serotonin signaling in zebrafish brain

  2022cites this paper
• TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT1A receptor agonist SEP-363856

  2022cites this paper
• Diurnal Alterations in Gene Expression Across Striatal Subregions in Psychosis.

  2022cites this paper
• Abnormal functional connectivity of the striatum in first‐episode drug‐naive early‐onset Schizophrenia

  2022cites this paper
• Male sex bias in early and late onset neurodevelopmental disorders: shared aspects and differences in autism spectrum disorder, attention deficit/hyperactivity disorder, and schizophrenia.

  2022cites this paper
• Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine

  2021cites this paper
• Impact of Group Art Therapy Using Traditional Chinese Materials on Self-Efficacy and Social Function for Individuals Diagnosed With Schizophrenia

  2021cites this paper
• Structures of the human dopamine D3 receptor-Gi complexes.

  2021cites this paper
• Current Limitations and Candidate Potential of 5-HT7 Receptor Antagonism in Psychiatric Pharmacotherapy

  2021cites this paper
• Correlation of abnormalities in resting state fMRI with executive functioning in chronic schizophrenia.

  2021cites this paper
• Augmentation With Pimavanserin in Treatment Refractory Schizophrenia: Case Report.

  2021cites this paper
• Contrasting Typical and Atypical Antipsychotic Drugs.

  2021cites this paper
• Serotonin 2B Receptor Interactions with Dopamine Network: Implications for Therapeutics in Schizophrenia

  2021cites this paper
• Beliefs: A challenge in neuropsychological disorders.

  2021cites this paper
• Toward personalized medicine in schizophrenia: Genetics and epigenetics of antipsychotic treatment.

  2021cites this paper
• Study on the relationship among dose, concentration and clinical response in Chinese schizophrenic patients treated with Amisulpride.

  2021cites this paper
• Modeling schizophrenia with iPS cell technology and disease mouse models.

  2021cites this paper
• Paliperidone 3-Month Injection for Treatment of Schizophrenia: A Narrative Review

  2021cites this paper
• Schizophrenia: Current and Perspectives

  2021cites this paper
• Pimavanserin augments the efficacy of atypical antipsychotic drugs in a mouse model of treatment-refractory negative symptoms of schizophrenia.

  2021cites this paper
• Evidence for Two Modes of Binding of the Negative Allosteric Modulator SB269,652 to the Dopamine D2 Receptor

  2021cites this paper
• Design, Synthesis and Biological Investigation of Flavone Derivatives as Potential Multi-Receptor Atypical Antipsychotics

  2020cites this paper
• Impaired working memory, cognitive flexibility and reward processing in mice genetically lacking Gpr88: Evidence for a key role for Gpr88 in multiple cortico‐striatal‐thalamic circuits

  2020cites this paper
• Nose-to-brain drug delivery

  2020cites this paper
• Effect of a 5-HT7 Receptor Antagonist on Reversal Learning in the Rat Attentional Set-Shifting Test.

  2020cites this paper
• Pharmacogenomics of Psychiatric Drugs

  2020cites this paper
• Unmet Needs in Patients with Schizophrenia

  2020cites this paper
• Pharmacogenomics in Precision Medicine: From a Perspective of Ethnic Differences

  2020influential citation
• Chemical puzzles in the search for new, flexible derivatives of lurasidone as antipsychotic drugs.

  2020cites this paper
• NQO1 regulates pharmaco-behavioral effects of d-amphetamine in striatal dopaminergic system in mice.

  2020cites this paper
• Comparison of clozapine monitoring and adverse event management in a psychiatrist-only and a clinical pharmacist-psychiatrist collaborative clinic

  2019cites this paper
• Effect of Cuscuta epithymum Acquainted with Risperidone on the Improvement of Clinical Symptoms and Cognitive Impairment in Patients with Schizophrenia: A Triple-Blind Randomized Placebo-Controlled Trial

  2019cites this paper
• Positive allosteric modulation of metabotropic glutamate receptor 5 modulates Akt and GSK3β signaling in vivo

  2019cites this paper
• Striatal volume and functional connectivity correlate with weight gain in early-phase psychosis

  2019cites this paper
• Effects of Amisulpride Adjunctive Therapy on Working Memory and Brain Metabolism in the Frontal Cortex of Patients with Schizophrenia: A Preliminary Positron Emission Tomography/Computerized Tomography Investigation

  2019cites this paper
• Schizophrenia patients using atypical medication perform better in visual tasks than patients using typical medication.

  2019cites this paper
• The associations between central nervous system diseases and haemostatic disorders.

  2019cites this paper
• Quercetin Reduces Cortical GABAergic Transmission and Alleviates MK-801-Induced Hyperactivity

  2018cites this paper
• Population-level pharmacogenomics for precision drug development in dementia

  2018cites this paper
• Striatal volume and functional connectivity predict weight gain in early-phase psychosis

  2018cites this paper
• Pharmacogenetics and cognitive symptoms in schizophrenia patients treated with antipsychotics.

  2018cites this paper
• Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity

  2018cites this paper
• CaMKIIα expression in a mouse model of NMDAR hypofunction schizophrenia: Putative roles for IGF-1R and TLR4.

  2018cites this paper
• Drug Repurposing Patent Applications April–June 2017

  2017cites this paper
• Drug Repurposing Patent Applications April–June 2015

  2015cites this paper